Clinical research into asthma, COPD, children, mucus, and coughing

The study examined nebulized 3% hypertonic saline in infants hospitalized with viral bronchiolitis. The treatment was evaluated for symptoms such as shortness of breath, mucus, and airway obstruction. The results indicate that hypertonic salt can help make mucus thinner and support breathing. In the context of hospitalized children, a shorter duration of illness or hospital stay was also described.

This controlled study examined long-term inhalation of hypertonic saline in people with cystic fibrosis. The treatment was linked to better mucus clearance, less trapped mucus, and better lung-related outcomes. Hypertonic salt was described as a safe and affordable supplemental treatment when used correctly. The research is important for the principle that salt inhalation can impact thick mucus.

This Cochrane review assessed multiple studies on nebulized hypertonic salt in cystic fibrosis. The review describes improvement in lung function in the short term, especially after about four weeks in adults and children from 12 years of age. In the long term, the effect remained less clear. The review also mentions support for mucus clearance but emphasizes that the strength of evidence varies per outcome.

Researchers investigated whether inhalation of hypertonic salt aerosol improves natural mucus clearance via the cilia. This was investigated in people with asthma and in healthy subjects. The results show that salt aerosol can strengthen mucociliary clearance: mucus is better displaced, and the airways can clean themselves more easily. This is a core mechanism for salt applications in the respiratory tract.

The study investigated osmotic stimuli in people with impaired mucus clearance. Osmotic stimuli are substances or conditions that attract fluid. Researchers examined whether such stimuli, such as hypertonic salt, make mucus more transportable. The results show that attracting fluid to the mucus can improve clearance, allowing the airways to clean themselves better.

This randomized pilot study investigated halotherapy in children with mild asthma. The children received treatments in a salt room with a halogenerator. The study examined airway reactivity, FeNO as a measure of airway inflammation, and quality of life. Particularly, the sensitivity of the airways improved: the airways responded less strongly to stimuli that can trigger shortness of breath or constriction. Larger follow-up studies remain necessary.

This systematic review and meta-analysis assessed randomized trials of mometasone nasal spray in children with enlarged adenoids. Researchers looked at nasal congestion, nasal breathing, adenoid size, and quality of life. The analysis describes improvement in nasal congestion and nasal breathing and a decrease in adenoid size. The research emphasizes the importance of free nasal breathing in children.

This pilot study investigated inhaled mannitol in people with cystic fibrosis. Mannitol attracts fluid and thus works via a principle comparable to hypertonic salt. After inhalation, better clearance of bronchial mucus was observed. Hypertonic salt also showed improvement in mucus clearance in the same study. The research supports the importance of drawing fluid into thick mucus.

The publication describes halotherapy as a supplemental treatment in people with chronic bronchitis. The emphasis is on long-term symptoms such as coughing, mucus, irritated bronchi, and shortness of breath. After treatment, fewer respiratory complaints, less coughing, less mucus, and calmer airways were described. Halotherapy was presented as a support within a broader treatment context.

No direct abstract available via the provided Google Scholar link. The research reference concerns halotherapy within the context of pulmonary rehabilitation. Literature on this subject mainly describes support for breathing, mucus clearance, airway comfort, and lung function. The topic positions halotherapy as a supplemental application for recovery-oriented care for people with chronic or long-term respiratory complaints.

This animal study investigated halotherapy in a COPD-like pathology and looked at lung function, inflammation, oxidative stress, and cell damage. The study describes improvement in lung function and a reduction in inflammation and pyroptosis, a form of inflammation-related cell damage. The action was linked to the inhibition of the NLRP3/ASC/Caspase-1 pathway. As it is animal research, translation to humans must be interpreted with caution.

The study investigated treatment in a halotherapy room with an artificial salt mine environment in people with asthma, allergic nasal complaints, chronic bronchitis, COPD-like symptoms, and recurrent respiratory infections. Researchers examined symptoms, inflammatory markers, immune responses, and airway reactivity. After treatment, fewer allergic reactions, less inflammatory activity, and a calmer airway response pattern were described.